Stiefel Laboratories, Inc. Enters into Strategic Collaboration with Allergan, Inc. to Expand and Strengthen Dermatologic Product Offering
Under the terms of the transaction, Stiefel will utilize Allergan'sproprietary technology and tazarotene in several different ways. Stiefel'sU.S. sales force will co-promote Allergan's TAZORAC(R) (tazarotene) todermatologists. Stiefel also will capitalize on its existing patent-protectedtechnology and Allergan's innovative tazarotene compound to bring uniquetherapeutic options to market for a common dermatological disease.
"This is a great opportunity," said Bill Humphries, Chief CommercialOfficer, Stiefel Laboratories. "TAZORAC(R) will provide the perfectcomplement to our acne portfolio, which also includes Duac(R), and it willallow Stiefel to offer best-in-class topical acne treatments to our customers.Given our long-standing and well-established presence in the dermatologyarena, we will be able make an immediate and important impact withTAZORAC(R)."
"Allergan is pleased to enter into a relationship with Stiefel to furtherstrengthen our presence in the medical dermatology market," said JulianGangolli, Allergan's Corporate Vice President and President of North AmericaPharmaceuticals. "The TAZORAC(R) brand is already widely recognized bydermatologists as an effective treatment option for acne and psoriasis.Stiefel's experience, expertise and capabilities in the dermatology marketwill be instrumental in helping to develop and market new products involvingtazarotene for global dermatological use."
According to Gavin Corcoran, Senior Vice President, Global Research andDevelopment, Stiefel Laboratories, the development agreements with Allerganare an integral component of Stiefel's overall growth strategy.
"This strategic partnership between Stiefel and Allergan epitomizes thetype of development agreements Stiefel is seeking to enhance our robustpipeline," Corcoran said. "We are able to integrate Stiefel's cutting-edgetechnology and products with Allergan's proprietary tazarotene compound inorder to provide physicians and patients with advanced solutions for theprevention and treatment of common skin conditions."
TAZORAC(R) (tazarotene) is a topical receptor-selective retinoid.TAZORAC(R) (tazarotene) Gel 0.1% is approved for mild-to-moderately severefacial acne, and TAZORAC(R) (tazarotene) Cream 0.1% is indicated for thetopical treatment of acne. TAZORAC(R) treats whiteheads (closed comedones),blackheads (open comedones), red pimples, (papules), and pimples containingpus (pustules).
Retinoids may cause fetal harm when administered to a pregnant woman.TAZORAC(R) Cream and Gel 0.1% are contraindicated in women who are or maybecome pregnant. If this drug is used during pregnancy, or if the patientbecomes pregnant while taking this drug, treatment should be discontinued andthe patient apprised of the potential hazard to the fetus. Women of child-bearing potential should be warned of the potential risk and use adequatebirth-control measures when TAZORAC(R) Cream or Gel 0.1% is used. Retinoidsshould not be used on eczematous skin, as they may cause severe irritation.The most frequent adverse reactions reported during clinical trials withTAZORAC(R) Cream 0.1% in the treatment of acne occurring in 10% to 30% ofpatients, in descending order, included desquamation, dry skin, erythema, andburning sensation. Full prescribing information for TAZORAC(R) is availableat www.tazorac.com.
About Stiefel Laboratories, Inc.
Founded in 1847, Stiefel Laboratories (a privately held company) is theworld's largest independent pharmaceutical company specializing indermatology. The company manufactures and markets variety of prescription andnon-prescriptio
You May Also Like